Soligenix

SNGX · Nasdaq · United States

Share price · SNGX

$0.25-0.14 (-36.16%) 3M

close as of 2026-11-18 · 24h delayed · vol 547K (3.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SNGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-9.9%
  2. 16 Nov 2026-10.2%
  3. 3 Jun 2026-36.0%
  4. 27 May 2026+70.6%
  5. 26 May 2026+30.8%
  6. 28 Apr 2026-70.4%
  7. 20 Apr 2026+10.4%
  8. 17 Dec 2025-19.1%

Share of unusual movement by asset

For each asset, the share of SNGX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Synthetic hypericin
events and moves
1663%
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—9%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
0Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Photosensitizer (visible-light activated)Small molecule
Indication not yet linked

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 April 2026Topline resultSynthetic hypericinFLASH2 Phase 3 interim analysis: halted for futility
17 December 2025Topline resultSynthetic hypericinPhase 2a Cohort 3 top-line results for SGX302 in psoriasis

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$0.4M$9.0M$1.1M-$1.4M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$1.0M$9.8M$2.0M-$1.7M operating cash flowreport ↗
2026-Q1$0$1.8M$6.0M$2.8Mreport ↗
2025-Q3—$1.6M$11M$2.5M-$2.9M operating cash flowreport ↗
2025-Q2—$1.7M$5.1M$2.7M-$2.7M operating cash flowreport ↗
2025-Q1—$2.2M$7.3M$3.2M-$1.9M operating cash flowreport ↗
2024-Q3—$1.0M$9.8M$1.7M-$2.9M operating cash flowreport ↗
2024-Q2$0$0.5M$9.4M$1.6M-$1.9M operating cash flowreport ↗
2024-Q1$0.1M$1.1M$7.1M$1.9M-$1.3M operating cash flowreport ↗
2023-Q3$0.1M$0.8M$10M$1.7M-$2.7M operating cash flowreport ↗
2023-Q2$0.2M$0.8M$13M$1.6M-$1.9M operating cash flowreport ↗
2023-Q1$0.3M$0.9M$10M$1.1M-$2.2M operating cash flowreport ↗
2022-Q3$0.2M$1.8M$17M$3.3M-$3.3M operating cash flowreport ↗
2022-Q2$0.2M$2.0M$20M$2.4M-$2.5M operating cash flowreport ↗
2022-Q1$0.2M$1.8M$23M$4.3M-$3.2M operating cash flowreport ↗
2021-Q3$0.2M$2.5M$29M$3.6M-$3.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$7.5M$7.9M$2.8M-$10M operating cash flowreport ↗

Soligenix reported revenue was not disclosed for fiscal 2025 (prior-year revenue was $0.12M), with R&D spend of $7.49M, up 43.5% YoY. Cash and equivalents totaled $7.94M, and the company reported a net loss of $11.08M, with quarterly net burn of $11.08M. No analyst expectations were provided in the material.

No financial guidance was provided. Soligenix continued advancing its confirmatory Phase 3 FLASH2 trial of HyBryte for cutaneous T-cell lymphoma, having completed enrollment of 50 patients for the planned Q2 2026 interim analysis, with top-line results expected in the second half of 2026; the first Data Monitoring Committee meeting reported no safety concerns. The company also completed the transfer of synthetic hypericin manufacturing to Sterling Pharma Solutions under its partnership agreement, while SGX302 for psoriasis remains in an ongoing Phase 2a study, SGX945 for Behçet’s disease completed its Phase 2a study, and SGX942 for oral mucositis continues to await a partnership for further development.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.1M$5.2M$7.8M$2.1M-$8.4M operating cash flowreport ↗
2023-FY$0.8M$3.3M$8.4M$1.5M-$8.6M operating cash flowreport ↗
2022-FY$0.9M$7.9M$13M$3.5M-$13M operating cash flowreport ↗
2021-FY$0.8M$8.4M$26M$3.1M-$12M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-12SCHABER CHRISTOPHER J · director, CHAIRMAN, CEO AND PRESIDENTDisposition to issuer (derivative)250——Form 4
2026-10-12Guarino Jonathan L. · CFODisposition to issuer (derivative)166——Form 4
2026-10-12Donini Oreola · CSODisposition to issuer (derivative)83——Form 4
2026-10-12LAPOINTE ANTHONY GREGG · directorDisposition to issuer (derivative)54——Form 4
2026-10-12Parks Diane L. · directorDisposition to issuer (derivative)6——Form 4
2026-10-12RUBIN ROBERT J. · directorDisposition to issuer (derivative)54——Form 4
2026-10-12ZELDIS JEROME B · directorDisposition to issuer (derivative)54——Form 4
2026-10-12SCHABER CHRISTOPHER J · director, CHAIRMAN, CEO AND PRESIDENTDisposition to issuer (derivative)250——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 15 reporting institutions held 0.3M shares ($307K, 1.1% of shares outstanding).

#InstitutionSharesValue
1GEODE CAPITAL MANAGEMENT, LLC120,267$142K
2VANGUARD CAPITAL MANAGEMENT LLC58,400$69K
3VANGUARD FIDUCIARY TRUST CO53,914$64K
4XTX Topco Ltd20,799$25K
5MORGAN STANLEY3,592$4K
6UBS Group AG2,346$3K
7SBI Securities Co., Ltd.402$474
8JPMORGAN CHASE & CO305$338
9Advisory Services Network, LLC209$247
10Plante Moran Financial Advisors, LLC209$247
11JONES FINANCIAL COMPANIES LLLP100$113
12CITIGROUP INC19$22
13CWM, LLC6$7
14OSAIC HOLDINGS, INC.2$2
15ALBION FINANCIAL GROUP /UT1$2